Liver biopsy Market 2019 is driven by Increasing number of biopsy procedures and Diseases with forecast till 2023

Liver biopsy is a procedure for obtaining samples from kidney tissue for analysis. Liver biopsy is used to diagnose various liver diseases such as nonalcoholic fatty liver disease, chronic hepatitis B or C, autoimmune hepatitis, and alcoholic liver disease. Along with the diagnosis it is also used to monitor the effect of treatment and determine whether the kidney transplant is working well or not. It consists of mainly two types; percutaneous biopsy, transjugular, and laparoscopic. In a percutaneous biopsy, a needle is inserted into the kidney through the skin, while in the surgical biopsy, an incision is made in the skin near the liver to take a tissue sample for examination.

Increasing prevalence of liver diseases and increasing number of biopsy procedures and diseases are the major drivers for the growth of the market. Furthermore, rising demand for new techniques for diagnosis of chronic and the need for better diagnostic and treatment methods drive the growth of the market. Major players in the developed countries lead the global market by offering new products and services to the developing countries and emerging economies. However, the high cost of diagnostic devices and instruments may hinder the market growth during the forecast period.

Get a free sample copy @ https://www.marketresearchfuture.com/sample_request/5534

Intended Audience

·         Research and Development (R&D) Companies

·         Ambulatory Care Centers

·         Academic Institutes and Universities

·         Biotechnology Companies

·         Medical Device Manufacturers

·         Medical Device Suppliers

·         Market Research and Consulting Service Providers

·         Potential Investors

Segmentations:

·         The global liver biopsy market is segmented on the basis of type, indication, and end user.

·         On the basis of diagnosis, it is segmented into percutaneous, transjugular, and laparoscopic biopsy.

·         On the basis of indication, it is segmented into the nonalcoholic fatty liver disease, chronic hepatitis B or C, autoimmune hepatitis, alcoholic liver disease, and others.

·         Based on the end user, it is segmented into hospitals & clinics, tertiary care centers, urology centers, and others.

Key Players:

·         Becton, Dickinson and Company,

·         MDxHealth,

·         Veran medical,

·         Medtronic,

·         Argon Medical Devices, Inc., M

·         auna Kea Technologies,

·         Boston Scientific Corporation,

·         Intact Medical Corp.,  C

·         . R. Bard, Inc.,

·         Leica Biosystems,

·         Cook Medical,

·         RI.MOS.,

·         Hologic, Inc.,

·         Sterylab, INRAD Inc.,

·         Fujifilm Medical Systems, and others.

Access the full report @ https://www.marketresearchfuture.com/reports/liver-biopsy-market-5534

Regional Analysis:

The Americas liver biopsy market is expected to exhibit extensive growth owing to technological advancement in the healthcare sector and increasing number of patient population suffering from liver diseases such as alcoholic liver disease and the high healthcare spending, and increasing government support for research & development will further boost the market growth. Additionally, liver disease is one of the major cause of mortality and morbidity in the Americas, thus boosting the market growth. As per the data from (CDC), in 2016, 38,170 deaths occurred due to liver diseases in the U.S. Additionally, 6.10% of the adults were diagnosed with liver diseases in the U.S. alone. As per the World Health Organisation (WHO), about 35 million people in the world die of chronic diseases, while 46% of the mortality is due to chronic diseases. According to National statistics in the U.K, liver diseases is the fifth most common cause of death across the globe. Liver diseases are the second leading cause of mortality amongst all digestive diseases in the U.S.